Local cytokine changes following fibrin-encapsulated mesenchymal stem cell-derived extracellular vesicle therapy in rat spinal cord injury

Abstract

Spinal cord injury (SCI) induces a prolonged and complex inflammatory response that contributes to secondary damage and influences functional recovery. Targeting this inflammatory milieu represents a promising therapeutic strategy. In this study, we investigated the effects of extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) and encapsulated in a fibrin matrix (FM) on cytokine regulation in a rat model of SCI 60 days post-injury. MSCs were isolated from rat adipose tissue, and EVs were obtained using cytochalasin B-induced vesiculation. The EVs were encapsulated in FM and applied locally to the injury site at doses of 5 and 10 μg. The SCI rat models were divided into four groups: untreated, treated with FM alone, treated with 5 μg of EVs in FM (FM+EVs5), and treated with a 10 μg dose (FM+EVs10). A multiplex assay was employed to quantify the levels of 23 cytokines in spinal cord tissue homogenates. The application of FM alone altered cytokine levels, notably increasing granulocyte colony-stimulating factor (G-CSF) levels by 2.8-fold, which may be attributed to the hemostatic and bioactive properties of fibrin. Treatment with MSC-derived EVs resulted in a dose-dependent modulation of inflammatory responses. In the FM+EVs10 group, pro-inflammatory cytokines interleukin (IL)-1β and IL-5, as well as the anti-inflammatory cytokine IL-10, were significantly reduced compared to both the untreated and FM-alone groups, with IL-10 levels decreasing 2.4-fold. A similar trend was observed for IL-17A, which was 1.6-fold lower in the FM+EVs10 group compared to the FM-alone group. These findings suggest that fibrin-encapsulated MSC-derived EVs can modulate inflammation in chronic SCI and warrant further investigation as a therapeutic approach for neuroprotection and tissue repair.

Keywords

Spinal cord injury / Mesenchymal stem cells / Extracellular vesicles / Fibrin matrix / Cytokine modulation / Rats

Funding

This study was funded by the subsidy allocated to Kazan Federal University for state assignment (No. FZSM-2023- 0011) in the sphere of scientific activities.

Conflict of interest

The authors declare that they have no competing interests.

References

[1] Ogurcov S, Shulman I, Garanina E, et al. Blood serum cytokines in patients with subacute spinal cord injury: A pilot study to search for biomarkers of injury severity. Brain Sci. 2021; 11(3):1-12. doi: 10.3390/brainsci11030322

[2] Sabirov D, Ogurcov S, Shulman I, et al. Comparative analysis of cytokine profiles in cerebrospinal fluid and blood serum in patients with acute and subacute spinal cord injury. Biomedicines. 2023; 11(10):2641. doi: 10.3390/biomedicines11102641

[3] Zhou X, Chu X, Yuan H, et al. Mesenchymal stem cell derived EVs mediate neuroprotection after spinal cord injury in rats via the microRNA-21-5p/FasL gene axis. Biomed Pharmacother. 2019;115:108818. doi: 10.1016/j.biopha.2019.108818

[4] Huang JH, Yin XM, Xu Y, et al. Systemic administration of exosomes released from mesenchymal stromal cells attenuates apoptosis, inflammation, and promotes angiogenesis after spinal cord injury in rats. J Neurotrauma. 2017; 34(24):3388-3396. doi: 10.1089/neu.2017.5063

[5] Romanelli P, Bieler L, Scharler C, et al. Extracellular vesicles can deliver anti-inflammatory and anti-scarring activities of mesenchymal stromal cells after spinal cord injury. Front Neurol. 2019;10:1225. doi: 10.3389/fneur.2019.01225

[6] Romanelli P, Bieler L, Heimel P, et al. Enhancing functional recovery through intralesional application of extracellular vesicles in a rat model of traumatic spinal cord injury. Front Cell Neurosci. 2022;15:795008. doi: 10.3389/fncel.2021.795008

[7] Levi AD, Okonkwo DO, Park P, et al. Emerging safety of intramedullary transplantation of human neural stem cells in chronic cervical and thoracic spinal cord injury. Clin Neurosurg. 2018; 82(4):562-575. doi: 10.1093/neuros/nyx250

[8] Murphy KC, Whitehead J, Zhou D, Ho SS, Leach JK. Engineering fibrin hydrogels to promote the wound healing potential of mesenchymal stem cell spheroids. Acta Biomater. 2017; 64:176-186. doi: 10.1016/j.actbio.2017.10.007

[9] Mukhamedshina YO, Akhmetzyanova ER, Kostennikov AA, et al. Adipose-derived mesenchymal stem cell application combined with fibrin matrix promotes structural and functional recovery following spinal cord injury in rats. Front Pharmacol. 2018;9:343. doi: 10.3389/fphar.2018.00343

[10] Mukhamedshina Y, Shulman I, Ogurcov S, et al. Mesenchymal stem cell therapy for spinal cord contusion: A comparative study on small and large animal models. Biomolecules. 2019; 9(12):811. doi: 10.3390/biom9120811

[11] Ragni E, De Luca P, Landoni S, et al. High efficiency protocol for platelet derived fibrin gel loaded with mesenchymal stromal cells extracellular vesicles. Regen Ther. 2024; 26:442-457. doi: 10.1016/j.reth.2024.06.020

[12] Kostennikov A, Kabdesh I, Sabirov D, et al. A comparative study of mesenchymal stem cell-derived extracellular vesicles’ local and systemic dose-dependent administration in rat spinal cord injury. Biology (Basel). 2022; 11(12):1853. doi: 10.3390/biology11121853

[13] Allison DJ, Ditor DS. Immune dysfunction and chronic inflammation following spinal cord injury. Spinal Cord. 2015; 53(1):14-18. doi: 10.1038/sc.2014.184

[14] Faden AI, Wu J, Stoica BA, Loane DJ. Progressive inflammation- mediated neurodegeneration after traumatic brain or spinal cord injury. Br J Pharmacol. 2016; 173(4):681-691. doi: 10.1111/bph.13179

[15] Kwiecien JM, Dabrowski W, Dąbrowska-Bouta B, et al. Prolonged inflammation leads to ongoing damage after spinal cord injury. PLoS One. 2020; 15(3):e0226584. doi: 10.1371/journal.pone.0226584

[16] Mukhamedshina YO, Zakirova EY, Galieva LR, Kostennikov AA, Akhmetzyanova ER, Rizvanov AA. Distribution and survival of transplanted adipose-derived mesenchymal stem cells in the spinal cord injury. Bionanoscience. 2017; 7(4):608-612. doi: 10.1007/s12668-017-0440-0

[17] Petter-Puchner AH, Froetscher W, Krametter-Froetscher R, Lorinson D, Redl H, van Griensven M. The long-term neurocompatibility of human fibrin sealant and equine collagen as biomatrices in experimental spinal cord injury. Exp Toxicol Pathol. 2007; 58(4):237-245. doi: 10.1016/j.etp.2006.07.004

[18] Kalsi P, Thom M, Choi D. Histological effects of fibrin glue and synthetic tissue glues on the spinal cord: Are they safe to use? Br J Neurosurg. 2017; 31(6):695-700. doi: 10.1080/02688697.2017.1359491

[19] Buchta C, Hedrich HC, Macher M, Höcker P, Redl H. Biochemical characterization of autologous fibrin sealants produced by CryoSeal and Vivostat in comparison to the homologous fibrin sealant product Tissucol/Tisseel. Biomaterials. 2005; 26(31):6233-6241. doi: 10.1016/j.biomaterials.2005.04.014

[20] Saed GM, Kruger M, Diamond MP. Enhanced matrix metalloproteinase expression by Tisseel in mesothelial cells, normal peritoneal fibroblasts, and adhesion fibroblasts. Eur J Plast Surg. 2006; 28(7):472-479. doi: 10.1007/s00238-005-0006-1

[21] Schachtrup C, Lu P, Jones LL, et al. Fibrinogen inhibits neurite outgrowth via beta 3 integrin-mediated phosphorylation of the EGF receptor. Proc Natl Acad Sci U S A. 2007; 104(28):11814-11819. doi: 10.1073/pnas.0704045104

[22] Adams RA, Bauer J, Flick MJ, et al. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med. 2007; 204(3):571-582. doi: 10.1084/jem.20061931

[23] Tabélé C, Montana M, Curti C, et al. Organic glues or fibrin glues from pooled plasma: Efficacy, safety and potential as scaffold delivery systems. J Pharm Pharm Sci. 2012; 15(1):124-140. doi: 10.18433/j39k5h

[24] He X, Yang L, Dong K, et al. Biocompatible exosome-modified fibrin gel accelerates the recovery of spinal cord injury by VGF-mediated oligodendrogenesis. J Nanobiotechnology. 2022; 20(1):360. doi: 10.1186/s12951-022-01541-3

[25] Afsartala Z, Hadjighassem M, Shirian S, et al. The effect of collagen and fibrin hydrogels encapsulated with adipose tissue mesenchymal stem cell-derived exosomes for treatment of spinal cord injury in a rat model. Iran J Biotechnol. 2023; 21(3):e3505. doi: 10.30498/ijb.2023.362229.3505

[26] Kodali M, Madhu LN, Reger RL, et al. Intranasally administered human MSC-derived extracellular vesicles inhibit NLRP3-p38/MAPK signaling after TBI and prevent chronic brain dysfunction. Brain Behav Immun. 2023; 108:118-134. doi: 10.1016/j.bbi.2022.11.014

[27] Pischiutta F, Caruso E, Cavaleiro H, Salgado AJ, Loane DJ, Zanier ER. Mesenchymal stromal cell secretome for traumatic brain injury: Focus on immunomodulatory action. Exp Neurol. 2022;357:114199. doi: 10.1016/j.expneurol.2022.114199

[28] Zhai X, Chen K, Yang H, et al. Extracellular vesicles derived from CD73 modified human umbilical cord mesenchymal stem cells ameliorate inflammation after spinal cord injury. J Nanobiotechnology. 2021; 19(1):274. doi: 10.1186/s12951-021-01022-z

[29] Zhao Y, Gan Y, Xu G, Yin G, Liu D. MSCs-derived exosomes attenuate acute brain injury and inhibit microglial inflammation by reversing CysLT2R-ERK1/2 mediated microglia M1 polarization. Neurochem Res. 2020; 45(5):1180-1190. doi: 10.1007/s11064-020-02998-0

[30] Shao M, Jin M, Xu S, et al. Exosomes from long noncoding RNA-Gm37494-ADSCs repair spinal cord injury via shifting microglial M1/M2 polarization. Inflammation. 2020; 43(4):1536-1547. doi: 10.1007/s10753-020-01230-z

[31] Ruppert KA, Nguyen TT, Prabhakara KS, et al. Human mesenchymal stromal cell-derived extracellular vesicles modify microglial response and improve clinical outcomes in experimental spinal cord injury. Sci Rep. 2018; 8(1):480. doi: 10.1038/s41598-017-18867-w

[32] Rong Y, Liu W, Lv C, et al. Neural stem cell small extracellular vesicle-based delivery of 14-3-3t reduces apoptosis and neuroinflammation following traumatic spinal cord injury by enhancing autophagy by targeting Beclin-1. Aging (Albany NY). 2019; 11(18):7723-7745. doi: 10.18632/aging.102283

[33] Shulman I, Ageeva T, Kostennikov A, et al. Intrathecal injection of autologous mesenchymal stem-cell-derived extracellular vesicles in spinal cord injury: A feasibility study in pigs. Int J Mol Sci. 2023; 24(9):8240. doi: 10.3390/ijms24098240